title: Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression.
abstract: To characterize the effects of intermittent interleukin (IL)-2 therapy on human immunodeficiency virus (HIV), 11 patients underwent detailed virological evaluation during a year of IL-2 therapy. Six patients showed a >0.5 log increase in plasma HIV during at least 1 IL-2 cycle, with 2 experiencing an increase in >50% of cycles. Three of the remaining 5 patients had a >0.5 log decrease during at least 1 IL-2 cycle, and the remaining patients exhibited <0.5 log changes. No changes in lymphoid (tonsil) levels of HIV were seen during the year. Quasi-species analysis in a separate cohort demonstrated that the virus induced by IL-2 most commonly resembled pre-IL-2 plasma quasi species. Thus, intermittent IL-2 does not result in sustained increases in either plasma or tissue levels of HIV and does not result in sustained expression of a previously silent quasi species.
authors.affiliation: Critical Care Medicine Department, Clinical Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-1662, USA. jkovacs@nih.gov
authors.forename: J A
authors.initials: JA
authors.lastname: Kovacs
authors.forename: H
authors.initials: H
authors.lastname: Imamichi
authors.forename: S
authors.initials: S
authors.lastname: Vogel
authors.forename: J A
authors.initials: JA
authors.lastname: Metcalf
authors.forename: R L
authors.initials: RL
authors.lastname: Dewar
authors.forename: M
authors.initials: M
authors.lastname: Baseler
authors.forename: R
authors.initials: R
authors.lastname: Stevens
authors.forename: J
authors.initials: J
authors.lastname: Adelsberger
authors.forename: L
authors.initials: L
authors.lastname: Lambert
authors.forename: R T
authors.initials: RT
authors.lastname: Davey
authors.forename: R E
authors.initials: RE
authors.lastname: Walker
authors.forename: J
authors.initials: J
authors.lastname: Falloon
authors.forename: M A
authors.initials: MA
authors.lastname: Polis
authors.forename: H
authors.initials: H
authors.lastname: Masur
authors.forename: H C
authors.initials: HC
authors.lastname: Lane
mesh_terms: D000328:Adult; D004334:Drug Administration Schedule; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000235:genetics* / Q000302:isolation & purification; D006801:Humans; D007262:Infusions, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D010802:Phylogeny; D016133:Polymerase Chain Reaction; D012367:RNA, Viral / Q000097:blood; D013997:Time Factors; D014759:Viral Envelope Proteins / Q000235:genetics; D019562:Viral Load
chemical_list: D007376:Interleukin-2; D012367:RNA, Viral; D014759:Viral Envelope Proteins